$8.570
-1.091 (-12.73%)Al cierre
Noticias de OPRX
Eventos de OPRX
OptimizeRx Partners with PulsePoint for Electronic Health Records
OptimizeRx announced a new partnership with PulsePoint that will make OptimizeRx's authenticated electronic health record and e-prescribing inventory available to PulsePoint clients. The integration builds on both companies' efforts to make HCP media more connected. OptimizeRx is expanding programmatic access to point of care inventory that historically was only purchased through direct or specialized channels, while PulsePoint brings that inventory and 250,000 incremental NPIs into its platform designed to coordinate HCP media activation, optimization, and reporting.
OptimizeRx Integrates Supply Path Optimization with The Trade Desk
OptimizeRx (OPRX) announced an integration with OpenPath, The Trade Desk's (TTD) supply path optimization solution, "making OptimizeRx's authenticated point of care inventory available directly to advertisers using The Trade Desk's leading, data-driven demand side platform," the company said.
OptimizeRx Appoints Andy D'Silva as CFO
OptimizeRx announced the company's board of directors has appointed Andy D'Silva to succeed Ed Stelmakh as CFO, effective January 1, 2027. The board has also appointed Heather Favazza as chief accounting officer, effective January 1, 2027. Stelmakh will continue serving as chief financial and strategy officer through December 31. During this period, he will work closely with D'Silva and Favazza to ensure an orderly transfer of responsibilities and continuity of execution. Stelmakh will stay on as a strategic advisor through the end of 2027 to ensure a smooth transition. D'Silva has most recently served as chief business officer. Favazza has been the company's corporate controller for the past eight years.
OptimizeRx Q2 Revenue at $20.5M, Exceeds Expectations
Reports Q2 revenue $20.5M, consensus $20.2M. Stephen L. Silvestro, OptimizeRx CEO commented, "Second quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and resilience in our operating model. While year-over-year revenue declined and contracted revenue remains below prior-year levels, these trends are concentrated among a small number of customers, and we are encouraged by increased investment across other portions of our customer base. Our continued investment in platform capabilities, including recent product launches and expanded programmatic initiatives, is strengthening customer engagement as we move into the 2027 planning cycle. Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance of $95 million to $100 million in revenue and $21 million to $25 million in adjusted EBITDA. We also expanded the long-term opportunity for OptimizeRx through three platform advancements: DeepIntent became the first healthcare demand-side platform (DSP) to integrate our authenticated electronic health record (EHR) network, we launched our patent-pending Natural Language Audience Builder, and we introduced CopayCue, our next-generation copay activation solution. These innovations strengthen our position in artificial intelligence (AI)-enabled audience intelligence, programmatic point-of-care activation, and clinical workflow engagement while creating opportunities for recurring growth.
Company Reiterates FY 2026 Guidance, Expects Revenue of $95M to $100M
The company said, "The Company is reiterating its fiscal year 2026 guidance, and expects revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million."
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.